Obesity drugs may be sold at just $149 a month, get covered under Medicare under a reported White House deal in the works

The White House is close to announcing a deal with drugmakers Eli Lilly and Novo Nordisk that would cut the price of obesity drugs to $149 per month in some cases and extend coverage to certain Medicare and Medicaid beneficiaries,

Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost

Obesity medicines coverage in U.S. Medicare Part D via a pilot programme, starting during 2026Introduction of lower prices for Novo Nordisk’s semaglutide medicines in U.S. Medicare Part D and Medicaid and in direct-to-patients cash channelNovo Nordisk currently expects an estimated negative low single-digit impact on global sales growth in 2026 Bagsværd,

Novo Nordisk Stock Rises After Earnings. It Cut Guidance on These Fears.

The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.
ConsumerAffairs

Medicare negotiates new prices for Ozempic and Wegovy

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) to set a negotiated price for
Feedback